TCRT
Alaunos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.13
+19.01%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.98
From 52W high−28.21%
Volume40.84M
Market cap$7.95M
P/E (TTM)—
P/S (TTM)2650.6x
Div yield—
Key dataOct 19, 2026
Open
$2.98
From 52W high
−28.21%
Volume
40.84M
Market cap
$7.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
70.1
MomentumView details →
1D Return
+19.01%
YTD Return
−4.41%
SummaryUpdated Jun 1, 2026
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a clinical-stage biotechnology company focused on developing innovative cancer treatments through engineered cell therapies. Originally founded as ZIOPHARM Oncology in 2003 and renamed Alaunos Therapeutics in January 2022, the Houston-based company has evolved from a traditional oncology drug developer into a specialized cell therapy company. The company went public in 2005 and has since pivoted to focus exclusively on adoptive T-cell receptor (TCR) engineered T-cell therapies for treating solid tumors, representing a cutting-edge approach in cancer immunotherapy.
Similar companies
Latest newsMore news →
Alaunos Therapeutics, Inc. shares rose about 200% on Tuesday, with trading volume of 191.48 million shares versus an average of 826,167.6d agoAlaunos Therapeutics, Inc. announced an oversubscribed $350 million private placement concurrent with its acquisition of Alaunos Therapeutics, Inc..7d agoAlaunos Therapeutics, Inc. announced its acquisition of Alaunos Therapeutics, Inc..7d ago